central retina
Showing 1 - 25 of 8,424
Epiretinal Membrane, Macular Pucker Trial in Moscow (Intraoperative ERM and ILM staining with their assessment and removal)
Recruiting
- Epiretinal Membrane
- Macular Pucker
- Intraoperative ERM and ILM staining with their assessment and removal
-
Moscow, Russian FederationS.N. Fedorov Nmrc "Mntk "Eye Microsurgery"
Mar 15, 2021
Diabetic Macular Edema Trial in United States (intravitreous aflibercept, Bevacizumab + Deferred Aflibercept Group)
Completed
- Diabetic Macular Edema
- intravitreous aflibercept
- Bevacizumab + Deferred Aflibercept Group
-
Campbell, California
- +53 more
Nov 28, 2022
Diabetic Macular Edema (DME) Trial in Worldwide (KHK4951, Aflibercept Injection)
Not yet recruiting
- Diabetic Macular Edema (DME)
- KHK4951
- Aflibercept Injection
-
Arcadia, California
- +29 more
Oct 31, 2023
Epiretinal Membrane Trial in United States (Immediate Vitrectomy, Deferred Vitrectomy)
Recruiting
- Epiretinal Membrane
- Immediate Vitrectomy
- Deferred Vitrectomy
-
Glendale, California
- +18 more
Aug 15, 2022
Neovascular Age-Related Macular Degeneration (nAMD) Trial in Worldwide (KHK4951, Aflibercept Injection)
Not yet recruiting
- Neovascular Age-Related Macular Degeneration (nAMD)
- KHK4951
- Aflibercept Injection
-
Arcadia, California
- +27 more
Oct 31, 2023
Diabetes, Diabetic Retinopathy, Diabetic Macular Edema Trial in Worldwide (THR-687 dose level 1, THR-687 dose level 2, THR-687
Terminated
- Diabetes Mellitus
- +2 more
- THR-687 dose level 1
- +3 more
-
Huntington Beach, California
- +24 more
Jul 19, 2022
Diabetic Retinopathy Trial in Spain, United Kingdom, United States (BI 765128, Sham comparator)
Recruiting
- Diabetic Retinopathy
- BI 765128
- Sham comparator
-
Dothan, Alabama
- +34 more
Jan 24, 2023
Diabetic Retinopathy Trial in Puerto Rico, United States (PDS Implant Pre-Filled with 100 mg/mL Ranibizumab, Intravitreal
Active, not recruiting
- Diabetic Retinopathy
- PDS Implant Pre-Filled with 100 mg/mL Ranibizumab
- Intravitreal Ranibizumab 0.5 mg Injection
-
Dothan, Alabama
- +75 more
Aug 3, 2022
Macular Edema, Retinal Vein Occlusion Trial in Worldwide (KSI-301, Aflibercept, Sham Procedure)
Active, not recruiting
- Macular Edema
- Retinal Vein Occlusion
- KSI-301
- +2 more
-
Phoenix, Arizona
- +140 more
Jul 20, 2022
Wet Age-related Macular Degeneration Trial in Puerto Rico, United States (KSI-301, Aflibercept, Sham Procedure)
Active, not recruiting
- Wet Age-related Macular Degeneration
- KSI-301
- +2 more
-
Phoenix, Arizona
- +65 more
Jun 2, 2022
Macular Edema Secondary to Retinal Vein Occlusion Trial in Worldwide (Aflibercept, VEGF Trap-Eye(Eylea, BAY86-5321)_higher dose,
Not yet recruiting
- Macular Edema Secondary to Retinal Vein Occlusion
- Aflibercept, VEGF Trap-Eye(Eylea, BAY86-5321)_higher dose
- +3 more
-
Fullerton, California
- +311 more
Apr 28, 2023
Diabetic Retinopathy Trial in United States (Fenofibrate, Placebo)
Recruiting
- Diabetic Retinopathy
- Fenofibrate 160mg
- Placebo
-
Glendale, California
- +32 more
Jan 26, 2022
Neovascular Age-Related Macular Degeneration Trial in United States (PDS Implant filled with 100 mg/mL Ranibizumab, Intravitreal
Completed
- Neovascular Age-Related Macular Degeneration
- PDS Implant filled with 100 mg/mL Ranibizumab
- Intravitreal Injections of 10 mg/mL Ranibizumab
-
Mesa, Arizona
- +76 more
Feb 28, 2022
Diabetic Retinopathy Trial in Puerto Rico, United States (Aflibercept Injection)
Recruiting
- Diabetic Retinopathy
- Aflibercept Injection
-
Beverly Hills, California
- +13 more
Jan 6, 2022
Diabetes, Diabetic Retinopathy, Diabetic Macular Edema Trial in Worldwide (THR-149 dose level 1, THR-149 dose level 2, THR-149
Recruiting
- Diabetes Mellitus
- +2 more
- THR-149 dose level 1
- +6 more
-
Beverly Hills, California
- +60 more
Aug 9, 2022
Proliferative Diabetic Retinopathy Trial in United States (Prompt Panretinal Photocoagulation, 0.5-mg Ranibizumab, Deferred
Completed
- Proliferative Diabetic Retinopathy
- Prompt Panretinal Photocoagulation
- +2 more
-
Phoenix, Arizona
- +47 more
Oct 27, 2021
Macular Edema, Branch Retinal Vein Occlusion Trial in Worldwide (Faricimab, Aflibercept, Sham Procedure)
Active, not recruiting
- Macular Edema
- Branch Retinal Vein Occlusion
- Faricimab
- +2 more
-
Phoenix, Arizona
- +151 more
Aug 4, 2022
Age-Related Maculopathy, Age-Related Maculopathies, Eye Diseases Trial in United States (RN6G, Placebo)
Completed
- Age-Related Maculopathy
- +4 more
- RN6G
- Placebo
-
Campbell, California
- +23 more
May 10, 2022
Age-Related Macular Degeneration, Geographic Atrophy Trial in United States (smaller incision, new generation implantable
Recruiting
- Age-Related Macular Degeneration
- Geographic Atrophy
- smaller incision, new generation implantable miniature telescope (SING-IMT)
-
Pasadena, California
- +7 more
Aug 5, 2022
Central Retinal Vein Occlusion Trial in United States (aflibercept, bevacizumab)
Completed
- Central Retinal Vein Occlusion
-
Phoenix, Arizona
- +71 more
Jun 11, 2021
Wet Macular Degeneration Trial in Worldwide (Faricimab, Aflibercept, Sham Procedure)
Macular Degeneration Trial in Worldwide (Ranibizumab)
Completed
- Macular Degeneration
- Ranibizumab
-
Gilbert, Arizona
- +101 more
Mar 11, 2022